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Available online 3 August 2016The health beneﬁt through the control of lipid levels in hyperlipidaemic individuals is evident from a large num-
ber of studies. The pharmacological options to achieve this goal shall be as speciﬁc and personalized as the rea-
sons for and co-factors of hyperlipidaemia. It was the goal of this study to reveal the impact of leoligin on
cholesterol levels and to deﬁne its mechanism of action.
Oral application of leoligin in ApoE−/−mice led to signiﬁcantly reduced total serum cholesterol levels and a re-
duction in postprandial blood glucose peak levels. In the absence of biochemical signs of toxicity, leoligin treat-
ment resulted in reduced weight gain in mice. The effects of leoligin on serum cholesterol levels may be due to
a direct inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) by a unique, non-statin-like binding
mode. Postprandial serum glucose peaks may be reduced by a mild peroxisome proliferator-activated receptor-
gamma (PPAR-γ) agonistic activity of leoligin. No effect on atherosclerotic plaque size was observed.
As a non-toxic, cholesterol-, peak glucose-, andweight gain-lowering compound, leoligin continues to fulﬁl char-
acteristics of a potential agent for the treatment of cardiovascular disease (CVD). The counterregulatory overex-
pression of hepatic HMGCR in leoligin treated animals possibly explains the missing permanent anti-
atherosclerotic effect.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Therapy1. Introduction
In 1913, Anitschkow and Chalatov showed that a cholesterol rich
diet in rabbits produces vascular lesions similar to atherosclerotic lesion
in humans [1]. Consequently, numerous animal, clinical, and epidemio-
logical studies elucidated the association and causality between
dyslipidaemia, the development of atherosclerosis, and coronary artery
disease (CAD) mortality. Important pioneering work which cleared the
way for the lipid-hypothesis of atherosclerosis included i) the identiﬁca-
tion of HMGCR as the rate-limiting enzyme of cholesterol biosynthesis
[2], ii) the discovery of the low-density lipoprotein (LDL) – receptorboratory, Medical University of
uck, Austria.
ard).
. This is an open access article under[3], iii) the FraminghamHeart study providing evidence for the associa-
tion between hypercholesterolemia and CAD [4,5], iv) the introduction
of HMGCR inhibitors, better known as statins [6], and v) the outcome
of the Coronary Primary Prevention Trail in 1984, showing that a reduc-
tion of total plasma- and LDL-cholesterol results in a lower incidence of
CAD [7,8]. Treatment options for atherosclerosis and CADwhich include
conservative approaches, such as physical exercise, diet, and pharmaco-
therapy [9] as well as interventional options, namely coronary artery
bypass grafting and percutaneous coronary intervention are versatile
and mainly depended on an individual's genetic background, life style,
and the stage of the disease. In the last two decades LDL-cholesterol
lowering statins have been shown to reduce mortality rates in primary
and secondary prevention of CAD [10,11]. Moreover, several studies in-
vestigated the effects of statins on atherosclerotic plaque progression
and demonstrated that an aggressive statin regiment results in athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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indispensable clinical importance and the fact that the discovery of
statins and their widespread use is a tremendous success story, the
search for new lipid lowering drugs is still a highly relevant task [9].
Leoligin, a compound isolated from the roots of Leontopodium nivale
subsp. alpinum Cass. (Edelweiss), has shown promising anti-atheroscle-
rotic characteristics in previous studies:Duwensee et al. investigated the
inﬂuence of leoligin on cholesteryl ester transfer protein (CETP), an en-
zyme that promotes the transfer of cholesteryl esters from high-density
lipoprotein (HDL) to, among other lipoproteins, LDL. Thus CETP inhibi-
tion raises HDL-cholesterol levels [15]. In the same study, leoligin was
also shown to inhibit CETP in human plasma. Further, transgenic CETP
mice given leoligin orally showed a trend towards reduced serum
LDL-cholesterol levels even though elevated CETP activity was mea-
sured, suggesting a possible lipid lowering effect due to other mecha-
nisms [16]. Additionally, the effects of leoligin on venous grafts in vitro
as well as in vivo were explored. Leoligin signiﬁcantly inhibited intimal
hyperplasia in human saphenous veins in vitro andneointima formation
in an in vivo venous bypass graft mouse model, without causing endo-
thelial damage. Treatment of primary vascular smooth muscle cells
and endothelial cells with leoligin revealed a signiﬁcant inhibitory effect
on smooth muscle cell proliferation by inducing cell cycle arrest in the
G1-phase and an inhibition of tumor necrosis factor-alpha (TNF-α)-me-
diated endothelial vascular cell adhesionmolecule-1 (VCAM-1) expres-
sion [17].
As mentioned above, leoligin was capable of reducing serum LDL-
cholesterol levels to a point which could not be explained by previous
ﬁndings. Accordingly, the basis of the present study is formed by the hy-
pothesis that leoligin reduces LDL-cholesterol levels in ApoE−/−mice
independent from its effects on CETP activity and shall thereby prevent
atherosclerotic plaque formation.
2. Material and methods
2.1. Leoligin
The isolation of leoligin from Edelweiss (Leontopodium nivale subsp.
alpinum) and its puriﬁcation (98% purity) has been described previously
[18].
2.2. Study design
Female 24 weeks-old ApoE−/− mice on C57BL/6J genetic back-
ground were obtained from Charles River (Sulzfeld, Germany) and
housed at 24 °C and a 12 h light/dark cycle in a virus/antibody-free en-
vironment of the Core Unit for Biomedical Research at the Medical Uni-
versity of Vienna. All animal experiments corresponded to the European
Union directive 2010/63/EU, were approved by Austrian veterinary au-
thorities, and were carried out in accordance to the “Principles of labo-
ratory animal care” formulated by the National Society for Medical
Research and the “Guide for the care and use of laboratory animals”,
prepared by the Institute of Laboratory Animal Resource and published
by the NIH.
ApoE−/−mice were fed a standard chow diet V1534–300 (ssniff,
Germany) and received drinking water ad libitum. After a short period
of acclimatization, ApoE−/− mice (n = 40; age = 29.5 ± 2 weeks)
were randomly divided into four treatment groups (n = 10 per
group) to receive either: vehicle control (0.1% dimethylsulfoxide;
Sigma-Aldrich, USA), 1 μM leoligin, 10 μM leoligin, or 50 μM leoligin dis-
solved in drinking water (all in 0.1% dimethylsulfoxide end concentra-
tion), respectively. Anaesthesia was carried out using 7.2 mg
xylasol + 96 mg ketamine (Bayer, Germany; Richter Pharma, Austria)
per kg body weight.
After 5 and 10 weeks of treatment fasting blood samples for bio-
chemical analyses were collected from the tail vein using a Microvette
CB300Z (Sarstedt, Germany). After 2 and 16 weeks of treatment,intraperitoneal glucose tolerance tests (IPGTT) were performed in
fasting mice (n = 5 per treatment group).
After 16 weeks of treatment, mice were anaesthetized (240 mg
xylasol + 1200 mg ketamine/kg body weight) and ﬁnal blood samples
were obtained by puncture of the inferior vena cava, mice were
sacriﬁced by removal of the heart and consequent terminal bleeding. Fi-
nally the aorta was extracted and carefully cleaned of all perivascular
tissue.2.3. Biochemical analyses
All blood sampleswere subjected to serumpreparation by centrifuga-
tion at 10.000 g and20 °C for 5min (Microfuge 22RCentrifuge, Beckmann
Coulter, USA). The serumwas immediately stored at−80 °C. The follow-
ing serum parameters were analysed at the Core Unit for Biomedical Re-
search at the Medical University of Vienna (using a Hitachi C311, Roche,
Switzerland): blood urea nitrogen (BUN), aspartate transaminase (AST),
alanine transaminase (ALT), lactate dehydrogenase (LDH), creatine ki-
nase (CK), total cholesterol, HDL-cholesterol, LDL-cholesterol, and
triglycerides.2.4. Assessment of atherosclerotic plaque area
The aorta was removed from its arch to its bifurcation, cleaned from
perivascular tissue, washed (phosphate buffered saline without calcium
and magnesium, 20 μM butylated hydroxytoluene, and 2 μM ethylenedi-
aminetetraacetic acid, pH = 7.4), opened longitudinally, pinned on a
black silicone plate with acupuncture needles (Standard Nr. 2,
0.20 × 15 mm, Asiamed, Germany) and ﬁxed overnight in a formal-su-
crose solution (containing phosphate buffer salinewith 4% paraformalde-
hyde, 5% sucrose, 20 μM ethylenediaminetetraacetic acid). The ﬁxed
aortas were then incubated with Sudan IV (0.5% Sudan IV, 35% ethanol,
50% acetone) for 15 min to stain atherosclerotic plaques. Destaining of
aortas was performed with 75% ethanol for 5 min. Pictures were taken
with a single-lens reﬂex camera (camera: Canon EOS 550D, lens: Canon
EF-S, f: 18–55 mm, IS, shooting mode: full automatic mode, Japan). Ath-
erosclerotic plaque area was analysed using Adobe Photoshop CS4 for
Windows (Adobe Systems, USA). Plaque area was calculated as percent-
age of either whole aortic area or segment area.2.5. Intraperitoneal glucose tolerance test
IPGTTswere performed in ﬁve randomly pickedmiceper group after
an overnight fast. Under anaesthesia the tail end was cut off and blood
glucose levels weremeasured using a Contour TS (Bayer, Germany) be-
fore, and 15min, 30min, 60min, 90min, and 120min after intraperito-
neal injection of 1 g glucose/kg (Braun, Germany) bodyweight.2.6. HMG-CoA-reductase activity assay
The activity of HMGCRwasmeasured in the presence of vehicle con-
trol, 0.5 μM leoligin, 5 μM leoligin, or 50 μM leoligin with a commercial
kit following the instructions of themanufacturer (Sigma-Aldrich, USA).2.7. Peroxisome proliferative-activated receptor-gamma activity assay
The ability of leoligin to interfere with PPAR-γwas measured in the
presence of vehicle control, 10 μM, 50 μM, and 100 μM leoligin andwith
the addition of the well described agonist rosiglitazone (supplied with
the assay kit indicated below, Indigo Biosciences, State College, USA)
and antagonist GW9662 (Sigma-AldrichM6191-5MG). A commercially
available kit (Indigo Biosciences, State College, USA) was used to deter-
mine PPAR-γ activity according the manufacturers` instructions.
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A ligand-based pharmacophore model for HMGCR inhibitors was
developed using the bioactive conformations of known inhibitors as
available in the Protein Data Bank (PDB) [19,20]. The 3D coordinates
of atorvastatin (PDB code 1hwk), mevastatin (1hw8), simvastatin
(1hw9), ﬂuvastatin (1hwi), cerivastatin (1hwj), and rosuvastatin
(1hwl) were aligned according to their positionswithin the HMGCR ac-
tive site using the reference point-based alignment implemented in
LigandScout 3.12 [21,22]. All statins mentioned above were also com-
piled into a 3D multiconformational “statin database”. This database
contained a maximum of 500 conformations per molecule and was cal-
culated using OMEGA (OMEGA, version 2.3.3; OpenEye Scientiﬁc Soft-
ware, Inc.: Santa Fe, NM, USA, 2009–2014) BEST settings as
implemented in LigandScout [23,24].
To evaluate binding orientations for leoligin within the HMGCR ac-
tive site, docking studies were performedwith GOLD using a genetic al-
gorithm for generating low-energy binding orientations. For docking,
the PDB entry 1hw9 (chain A)was chosen because of its good resolution
and the co-crystallized ligand simvastatin, which has a similar size as
leoligin. The binding site was deﬁned as an 11 Å sphere centred on
Lys691. To ensure an optimal binding orientation, two hydrogen bond
constraints were set: one with Lys691 and the other one with Ser684.
In addition, Arg590 was set ﬂexible. Goldscore was used as a scoring
function. The program was set to deﬁne the atom types of the protein
and ligand. The docking settings were validated by re-docking simva-
statin into the crystal structure to ensure that the program is able to re-
produce the binding orientation of the co-crystallized ligand.
2.9. In silico modelling (PPAR-γ)
Docking experiments were performed using AutoDock Vina 1.1 as
implemented in LigandScout 4.09, using default settings. For docking,
the PDB entry 2xkw (human PPAR-γ in complex with pioglitazone)
[25] was selected. As positive control, the co-crystallized ligand pioglit-
azonewas docked into the binding sitewithout prior information on the
ligand geometry or its orientation within the ligand binding domain.
Out of the nine generated pioglitazone poses, the three most similar
ones had RMSD values between 0.701 and 1.169 in comparison to the
co-crystallized structure. This conﬁrmed that the program settings
were suitable to reproduce the correct pioglitazone binding geometry
and its experimentally determined orientation within the binding site.
For the prediction of the binding pose of leoligin, the same workﬂow
was followed as for pioglitazone.
2.10. Immunoﬂuorescence staining of HMG-CoA-reductase on liver sections
Immunoﬂuorescence staining was performed on 5 μm liver parafﬁn
sections. Liver tissue sections were subjected to standard
deparafﬁnization technique followed by heat-mediated antigen retriev-
al with citrate buffer (pH = 6). Permeabilisation was achieved using
0.2% Triton X-100 in tris-buffered saline (TBS) for 5min. Blocking of un-
speciﬁc binding sites was performed using 1% bovine serum albumin
(BSA) and 10% goat serum in TBS for 30 min. Slides were incubated
with the primary antibody (anti-HMGCR antibody, NBP1-91996,
Novus Biologicals, USA) overnight. Thereafter, liver tissue sections
were incubated with the secondary antibody for 1 h in the dark, using
Alexa Flour 488 goat anti-rabbit antibody (A11034, Life Technologies,
USA). After washing in TBS with 0.1% Tween-20 (TBST), cell nuclei
were stained with 5% propidium-iodide (PI) in TBS for 1.5 min. Slides
were then mounted in ProLong Gold antifade reagent (P36930, Life
Technologies, USA). Image acquisition was conducted using a LSM 510
Meta attached to an Axioplan 2 imaging MOT using ZEN software
2008 (Zeiss, Germany). Quantiﬁcation of HMGCR area was performed
using Adobe Photoshop CS4 for Windows (Adobe System, USA).HMGCR positive area was calculated in pixel and then related to the
number of cell nuclei.
2.11. Hepatic protein extraction, Western blotting and immunodetection
For protein extraction, frozen liver samples of each mouse were cut
in small pieces on ice and then suspended in RIPA-buffer (containing
50 mM TrisCl, 150 mMNaCl, 0.02% sodium azide, 0.1% SDS, 1% Nonidet
P-40, 0.5% sodium deoxycholate, and protease inhibitors). Samples
were sonicated (Ultrasonic Processor UP200St, Hielscher, Germany)
and the suspension was centrifuged at 10.000 rpm for 10 min at 4 °C
(Microfuge 22R Centrifuge, Beckmann Coulter, USA). After separation
of insoluble parts, protein concentrations were determined using the
Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (23225, Thermo Sci-
entiﬁc Fisher, USA) according to themanufacturers` instructions. There-
after proteins were separated on a 10% sodium dodecyl sulphate-
polyacrylamide gel (SDS-PAGE) and blotted onto nitrocellulose mem-
branes. Subsequent to blocking of unspeciﬁc binding sites with phos-
phate buffered saline without calcium and magnesium (PBS−/−)
containing 3% non-fat diet milk powder and 0.05% Tween-20, immuno-
stainingwas performed for ATP-binding cassette transporter A1 (ABCA-
1) (mouse anti-ABCA-1 antibody; ab18180, Abcam, USA), scavenger re-
ceptor class B member 1 (SR-B1) (rabbit anti-SR-B1 antibody; NB400-
104H, Novus Biologicals, USA), and LDL-receptor (LDL-R) (rabbit anti-
LDL-R antibody; 3939–100, BioVision Inc., USA). Following 3 washing
steps in PBS−/− with 0.05% Tween-20, membranes were incubated
with either horse anti-mouse horseradish peroxidase (HRP)-linked an-
tibody (7076, Cell Signaling Technology, USA) or goat anti-rabbit HRP-
linked antibody (32460, Thermo Fisher Scientiﬁc, USA). After 3washing
steps, chemiluminescent detection was performed using either Super
Signal West Femto Maximum Sensitivity Substrate (34096, Thermo
Fisher Scientiﬁc, USA) or Super Signal West Pico Chemiluminescent
Substrate (34011, Thermo Fisher Scientiﬁc, USA), followed by exposure
of X-ray ﬁlms (34091, Thermo Fisher Scientiﬁc, USA). Densitometric
analysis of Western blot images was performed using ImageJ software.
2.12. Oil Red O staining of frozen liver sections and quantiﬁcation
Liver sections were cut frozen (5 μm), air dried and then ﬁxed in ice-
cold formalin (7.5%; SAV-LP, Germany) followed by multiple washing
steps with distilled water (B. Braun, Germany). Thereafter sections were
air dried for approximately 1 h, incubated in pre-warmed (60 °C) propyl-
ene glycol (100%; Sigma-Aldrich, USA) for 3 min and then stained with a
pre-warmed (60 °C) Oil Red O solution (0.5 g Oil Red O; Sigma-Aldrich,
USA in 100 ml propylene glycol) for 60 min at 60 °C. Subsequently
sections were differentiated with propylene glycol (85%) for 5 min,
washed with distilled water twice for 3 min and then cell nuclei
were stained with Mayer's Haematoxylin (Sigma-Aldrich, USA) for
1 min. Finally, sections were washed under running tap water for
6 min, then 3 times for 5 min with distilled water, mounted with
Aquatex (Merck, Germany), air dried for 30 min and sealed with
Entelan (Merck, Germany). Consequently, images were taken with
Axiocam (Zeiss, Germany) and quantiﬁcation of Oil Red O positive
area was conducted using Adobe Photoshop CS4 for Windows
(Adobe Systems, USA). Therefore, Oil Red O positive area was calcu-
lated in pixel in relation to total picture pixels.
2.13. Statistical analyses
Data was initially analysed for Gaussian distribution using Kolmogo-
rov-Smirnov test with Lilliefors correction. Differences between the two
groupswere compared by either non-parametricMann–Whitney U test
or unpaired Student's t-test as applicable depending on the distribution
of the tested variables. Two-sided ANOVA for comparison of multiple
treatment groups was used. A value of p b 0.05 was considered
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20.0 for Windows (SPSS Inc., USA).
3. Results
3.1. Leoligin reduces cholesterol levels (in vivo) in ApoE−/− mice
Leoligin has previously been shown to interact both, in vitro and in
vivo,with CETP by our group [16]. In order to test for the CETP-speciﬁc-
ity of this cholesterol-lowering effect, we analysed the effect of leoligin
in ApoE−/−mice, which do not express CETP, and surprisingly found a
signiﬁcant reduction of cholesterol levels in thesemice. After 2weeks of
treatment, mice exposed to 1 μM, 10 μM, and 100 μM leoligin hadFig. 1. Leoligin reduces cholesterol levels in ApoE−/−mice. Cholesterol levels were measured
n=9, Leoligin 10 μM:n=7, Leoligin 50 μM: n=8), and after 16weeks (E, F; control: n= 9, Le
or vehicle control, respectively. (A, C, E) show the total cholesterol, LDL-cholesterol and HDL-ch
cholesterol/HDL-cholesterol ratio in the different treatment groups. Level of signiﬁcance: *p b 0
experiment which included a 100 μM group instead of a 50 μM group.signiﬁcantly lower total serum cholesterol (p b 0.001, p = 0.001, and
p = 0.028 respectively) and LDL-cholesterol (p b 0.001, p b 0.001, and
p = 0.014 respectively) levels compared to the vehicle control group
(Fig. 1A). Moreover, the total cholesterol/HDL cholesterol and the LDL-
cholesterol/HDL-cholesterol quotients were signiﬁcantly lower in the
1 μM and 10 μM leoligin treatment group (p b 0.001 and p = 0.008, re-
spectively) when compared to the vehicle control group (Fig. 1B). In
order to test the duration of the cholesterol lowering effects of leoligin,
we also analysed lipid levels at a later time point. After 5 weeks of treat-
ment, total cholesterol and LDL-cholesterol remained signiﬁcantly re-
duced in ApoE−/− mice treated with 1 μM leoligin (p = 0.023 and
p = 0.012 respectively), whereas there was an increase in HDL-choles-
terol levels in the 50 μM leoligin group (p = 0.028) resulting in aafter 2 weeks (A§, B§; n = 4 per group), after 5 weeks (C, D; control: n = 7, Leoligin 1 μM:
oligin 1 μM: n=9, Leoligin 10 μM:n=9, Leoligin 50 μM:n=7) of treatmentwith leoligin
olesterol, whereas (B, D, F) depict the total cholesterol/HDL-cholesterol ratio and the LDL-
.05, **p b 0.01, and ***p b 0.001. §The two week serum samples originate from a separate
Table 1
Effect of leoligin on serum triglyceride levels in ApoE−/−mice after 5 and 16 weeks of treatment.
Control Leoligin 1 μM Leoligin 10 μM Leoligin 50 μM
5 weeks mean (±SD)
p-value
40.57 (±5.71) 38.78 (±8.3)
0.634
36.57 (±10.45)
0.329
38.38 (±10.31)
0.626
16 weeks mean (±SD)
p-value
34.78 (±11.37) 29.11 (±7.17)
0.224
33.22 (±7.9)
0.74
24.29 (±7.34)
0.053
SD= standard deviation.
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and 5 weeks of treatment a clear dose-effect relationship between
leoligin concentration and cholesterol ratios was observable as higher
leoligin concentrations resulted in improved LDL-/HDL-cholesterol ra-
tios. After 16 weeks of treatment we observed a signiﬁcant increase in
the LDL-/HDL-cholesterol ratio in the 10 μM leoligin group (p =
0.031), but no signiﬁcant differences in total serum cholesterol levels,
LDL-cholesterol levels, and HDL-cholesterol levels (Fig. 1E and F).
Serum triglyceride levels were assessed after 5 and 16 weeks of
treatment and did not show any signiﬁcant alterations between the dif-
ferent treatment groups (Table 1). To exclude any toxic effects of
leoligin in ApoE−/− mice, we analysed BUN, AST, ALT, LDH, and CK,
but found no signiﬁcant increases in leoligin-treated mice compared
to controls after 16 weeks of treatment (Table 2).
3.2. Leoligin inhibits 3-hydroxy-3-methylglutaryl-CoA-reductase
To investigate the mechanism by which leoligin might alter choles-
terol levels in our animal model of ApoE−/−mice, we analysed its ef-
fect on the activity of HMGCR in vitro. Surprisingly, 0.5 μM, 5 μM, and
50 μM leoligin signiﬁcantly reduced HMGCR activity in a cell free bio-
chemical assay. 5 μMand 50 μMwere able to inhibit HMGCR to a similar
extent as a 100 μM (ﬁnal concentration) pravastatin solution (Fig. 2A).
3.3. Leoligin shares structural features with known HMG-CoA reductase
inhibitors
In order to test for a potential statin-like binding and inhibition of
HMGCR by leoligin, a molecular modelling workﬂow was employed.
Bioactive conformations of statins co-crystallizedwithin theHMGCR ac-
tive site were aligned (Fig. 2B) and investigated for common protein-li-
gand interactions with the enzyme. The alignment of the bioactive
conformations allowed for a positioning of pharmacophore features
representing characteristic protein-ligand interactions: Three hydro-
phobic groups indicated positions for lipophilic protein-ligand contacts
and four hydrogen bond acceptors represented the hydroxyl and car-
boxylic acidic groups on the opened lactone moiety (Fig. 2C).
For the leoligin mapping, a set of 3D conformations was calculated.
Due to the chemical structure of leoligin, it was unlikely that the com-
pound would map the statin model as it was. Particularly the four hy-
drogen bond acceptor features would be a challenge to map any
compound, which has a chemical structure different from the statin
class. We therefore allowed leoligin to leave out any two out of theTable 2
Biochemical parameters in ApoE−/−mice after 16 weeks of leoligin treatment.
Control
BUN (mg/dl) mean (±SD)
p-value
14.33 (±2)
AST (U/l) mean (±SD)
p-value
35.89 (±5.04)
ALT (U/l) mean (±SD)
p-value
18.22 (±7.92)
LDH (U/l) mean (±SD)
p-value
235.11 (±82.87)
CK (U/l) mean (±SD)
p-value
77.44 (±19.77)
SD= standard deviation, BUN = blood urea nitrogen, AST = aspartate transaminase, ALT = afour hydrogen bond acceptor features during the ﬁtting. After having
done so, leoligin mapped well into the model, which suggests that
leoligin is able to form similar protein-ligand interactions with
HMGCR as statins do (Fig. 2D).
3.4. Molecular modelling suggests a unique binding mode of leoligin to
HMG-CoA-reductase
A binding mode of leoligin within the HMGCR active site was sug-
gested by molecular docking. Leoligin showed binding interactions
comparable to the ligand-based pharmacophoremodel and to the bind-
ing interactions of simvastatin. It shared a similar hydrogen bond net-
work as simvastatin, and its hydrophobic side chains occupied the
hydrophobic areas of the binding site.Whereas the statins form ionic in-
teractions with Arg590 (Fig. 2E), leoligin established hydrogen bonds
with this amino acid (Fig. 2F).
3.5. Effect of leoligin on atherosclerotic endpoints in ApoE−/− mice
In the next step we set to determine whether the beneﬁcial alter-
ation of lipid proﬁles by leoligin in ApoE−/−mice would result in re-
duced atherosclerosis in our model system. Therefore, we explanted
the aortas from the aortic arch to the bifurcation after 16weeks of treat-
ment, stained the atherosclerotic plaques with Sudan IV and calculated
the atherosclerotic plaque area as percentage of the whole aorta or seg-
ments of the aorta; i.e. ascending aorta plus aortic arch, descending
aorta plus abdominal aorta, aortic bifurcation area. In our experimental
setting, there was no signiﬁcant effect of a systemic leoligin application
on atherosclerotic plaque area (Fig. 3A and B). Further, we also analysed
plaque morphology (plaque structure, cap thickness) in order to reveal
potential alterations in plaque stability. To do so, aortic arch specimens
were stained for alpha-smooth muscle actin (smooth muscle cells),
von-Willebrand Factor (endothelial cells), and cell nuclei using TO-
PRO-3. Image analyses of the samples and comparison between groups
did not reveal signiﬁcant differences between the leoligin groups and
the control (for details see Online Supplementary Information and Sup-
plementary Fig. S1A and S1B).
3.6. Long-term treatment with leoligin increases hepatic HMG-CoA-reduc-
tase expression in ApoE−/−mice
As the cholesterol-lowering effect of leoligin had disappeared after
16 weeks of treatment and no effect of leoligin on plaque area andLeoligin 1 μM Leoligin 10 μM Leoligin 50 μM
16.44 (±2.24)
0.077
15.56 (±1.67)
0.178
19.43 (±8.14)
0.252
29.44 (±3.47)
0.006
66.56 (±46.41)
0.796
29.71 (±9.74)
0.121
15.56 (±3.54)
0.489
28.44 (±15.77)
0.108
17.57 (±7)
0.758
255.33 (±117.04)
0.678
419.67 (±317.42)
0.222
248.29 (±84.04)
0.758
84.78 (±29.13)
0.541
136 (±139.06)
0.222
62.43 (±15.7)
0.123
lanine transaminase, LDH= lactate dehydrogenase, CK = creatine kinase.
Fig. 2. Leoligin inhibits 3-hydroxy-3-methylglutaryl-CoA-reductase and molecular
modelling and docking of leoligin with HMG-CoA-reductase suggests an unconventional
binding mode. (A) HMGCR activity is shown as percent of the activity control (activity
control equals 100%). Leoligin signiﬁcantly inhibits the activity of HMGCR to a similar
extent as 100 μM pravastatin in vitro. **p b 0.01, ***p b 0.001. n = 4 for each data point.
(B) Alignment of bioactive conformations of statin molecules bound to HMGCR. (C)
Chemical functionalities shared by different statins. (D) Leoligin mapped to the common
feature statin model. All but two chemical features (red spheres) were mapped by the
ligand, suggesting similar protein-ligand interaction proﬁles compared to the currently
used statins. (E) Simvastatin bound to HMGCR in the PDB entry 1hw9. (F) The statin
forms hydrophobic contacts, hydrogen bond acceptors and donors, and a charged
interaction with Arg590. Suggested binding orientation of leoligin within the HMGCR
active site. Similar to simvastatin, hydrophobic contacts and hydrogen bond networks
also including Arg590 are formed. Interaction types are colour-coded: red – hydrogen
bond acceptor, green – hydrogen bond donor, yellow – hydrophobic, red star – negative
charge.
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for the loss of leoligin activity. Accordingly, we ﬁrst performed HMGCR
staining in mouse liver sections. After two weeks of treatment with
leoligin no differences in hepatic HMGCR expression were observed
compared to the vehicle control group (Fig. 4A and B). However, after
16 weeks of treatment, paralleled by the disappearance of the drug ef-
fect on lipid levels and in the absence of inhibition of plaque formation
by leoligin, we could observe a signiﬁcant increase in hepatic HMGCR
expression by leoligin (1 μM (p = 0.04) and 50 μM (p= 0.031)) com-
pared to the control (Fig. 4C and D).
Further, we performed an Oil Red O staining to determine hepatic
lipid and cholesterol depositions andmeasured liver andwhole body
weight at the end of the experiment. Compared to the control group,
Oil Red O positive area was signiﬁcantly increased in the 1 μM
leoligin group (Fig. 5A and B), indicating more lipid/cholesterol de-
position in the liver. In addition, liver weight/body weight ratio
was slightly but signiﬁcantly increased in this group (Fig. 5C).However, absolute liver weight did not differ signiﬁcantly between
the groups, and also relative liver/body weight ratio (apart from
the above exception) was not affected by the treatment. Microscopic
morphologic inspection of the liver parenchyma did not reveal gen-
eral alterations in liver architecture.3.7. Low concentrations of leoligin may slightly increase LDL-receptor
activity
In order to test for potential alterations in liver cholesterol uptake
and metabolism, Western blot analyses of liver tissue homogenate for
ABCA-1, SR-B1, and LDL-R, as well as in vitro cholesterol uptake and ef-
ﬂux analyses were performed. The increased cholesterol deposition in
the 1 μM leoligin group cannot be explained by increased uptake of
HDL-cholesterol via SR-B1 since expression of this protein was not af-
fected (Fig. 5D and Supplementary Fig. S3). Additionally, HDL function
seemed preserved as shown by measurement of HDL mediated choles-
terol efﬂux in leoligin treated J774 mouse macrophages (Supplementa-
ry Fig. S2B). This is in line with additional in vitro experiments where
leoligin did not affect HDL-cholesterol uptake in HEK293 cells (Supple-
mentary Fig. S2A). However, the observed increased lipid content in the
livermight be explained by enhanced LDL-R activity.Western blot anal-
ysis of liver specimen showed at least a trend towards an increased LDL-
R expression inmice treatedwith 1 and 10 μMleoligin. (Fig. 5D and Sup-
plementary Fig. S3).3.8. Leoligin reduces peak blood glucose levels in ApoE−/−mice
Because changes of lipid levels may also be caused by disturbed glu-
cose metabolism, wemeasured fasting glucose levels and glucose toler-
ance after 2 and 16 weeks of treatment with leoligin or vehicle control.
We did not observe any signiﬁcant differences in basal fasting glucose
values between the different treatment groups at either time point.
However, after 2 weeks of treatment, peak blood glucose levels
60 min after intraperitoneal injection of glucose were signiﬁcantly
lower in the 10 μM and 50 μM leoligin group compared to the control
(p = 0.009 and p = 0.002, respectively) (Fig. 6A). The intraperitoneal
glucose tolerance test was also performed after 16 weeks of treatment,
showing only a non-signiﬁcant trend for reduced serum glucose peak
values under leoligin treatment (Fig. 6B).3.9. Leoligin is a weak PPAR-γ agonist in vitro and interacts with the ligand
binding domain of PPAR-γ in in silico molecular modelling
Since PPAR-γ agonists are known to increase insulin sensitivity
without affecting fasting glucose, we hypothesized that leoligin might
interact with PPAR-γ activity. Based on the results of the IPGTT, where
mice treated with leoligin had signiﬁcantly lower peak blood glucose
levels after intraperitoneal injection of glucose, we tested leoligin in a
cell-based PPAR-γ activity assay. The cell based assay showed, that
leoligin slightly increases (not statistically signiﬁcant) PPAR-γ activity
when applied alone (Fig. 7A). In the presence of the PPAR-γ agonist
(rosiglitazone), leoligin decreased rosiglitazone induced PPAR-γ activi-
ty signiﬁcantly (Fig. 7B). On the contrary, when the PPAR-γ antagonist
(GW9662)was added to the cells leoliginwas, once again, capable of in-
creasing PPAR-γ activity (non-signiﬁcantly; p = 0.074) (Fig.7C).
To describe the interaction of leoligin with PPAR-γ more precisely,
molecular modelling and docking experiments were performed. Leoligin
was predicted to bind to the PPAR-γ ligand binding domain at a similar
site that is described for pioglitazone (Fig. 7D). Leoligin forms two hydro-
gen bond acceptors with Cys285 and Ser342 (red arrows, Fig. 7E and F).
Additionally, extensive hydrophobic contacts are established between
leoligin and PPAR-γ (yellow spheres, Fig. 7E and F).
Fig. 3. Effect of leoligin on atherosclerotic plaque formation in ApoE−/−mice. (A) Atherosclerotic plaque area is given as percentage of thewhole aorta (total), ascending aorta and aortic
arch (asc. aorta + arch), descending aorta and abdominal aorta (desc. + abd. aorta) and aortic bifurcation (bifurcation) after 16 weeks of treatment with leoligin and vehicle control
(control: n = 9, Leoligin 1 μM: n = 9, Leoligin 10 μM: n = 9, Leoligin 50 μM: n = 7). (B) Aortas were stained with Sudan IV to detect atherosclerotic plaques. Representative images
are shown.
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In order to test for a possible metabolisation of leoligin at later time
point as a potential explanation for the loss of leoligin's cholesterol low-
ering activity after 16 weeks of treatment, we set to determine leoligin
concentrations in all mouse serum samples andmouse liver tissue sam-
ples using a novel gas chromatography –mass spectrometry-based ap-
proach. Surprisingly, leoligin could not be detected in our samples,
neither at an early nor a late time point. The lower limit of detection
(LOD) for serum was 0.5 μM and for liver 1 μM – for details see Online
Supplementary Information.3.11. Leoligin reduces weight gain in ApoE−/− mice
As part of our studies on the effects of leoligin in Apo E−/−mice,
we also measured body weight of the mice throughout the project.
There were no differences in whole body weight between the 1 μM
leoligin, 10 μM leoligin and vehicle control group. However, the
50 μM leoligin treated group gained signiﬁcantly less body weight
compared to the control group (3.66 ± 1.29 g vs. 5.13 ± 0.67 g;
p = 0.01; Fig. 8A) over a time period of 16 weeks. To rule out a pos-
sible inﬂuence of reduced energy intake, we measured the nutrition
intake for all mice over time. No signiﬁcant difference between the
groups and the control could be observed (see Supplementary Fig.
S4A).4. Discussion
Leoligin, a compound isolated from the roots of the alpine plant
Edelweiss, was shown to have beneﬁcial effects on venous bypass
graft patency as well as on serum cholesterol levels by interfering
with CETP activity [16,17]. Dyslipidaemia is known as amajor risk factor
and driving force of atherosclerosis and subsequent CAD-development.
To diminish the risk of development (primary prevention) and especial-
ly to reduce complications when clinically manifest (secondary preven-
tion), CAD patients essentially rely on dyslipidaemia treatment. Among
the treatment options such as diet changes and physical exercise,
HMGCR inhibitors, statins in particular, are themajor players in treating
high total- and LDL-cholesterol serum levels and have become an indis-
pensable part of CAD-management in the recent past [26]. Despite their
huge clinical importance we have to deal on the one hand with serious
adverse side effects (e.g. effects on skeletal muscle such as myositis or
rhabdomyolysis [27] or a potential risk of developing new-onset diabe-
tes mellitus [28]) and on the other hand with the non-achievement of
recommended cholesterol-lowering goals with statins only [9]. Hence,
the search for new lipid lowering agents is still a highly relevant task.
In this study, we identiﬁed leoligin as a potential new cholesterol-
lowering drug that signiﬁcantly reduces total serum cholesterol as
well as LDL-cholesterol and leads to favourable cholesterol ratios in
ApoE−/− mice via the inhibition of HMGCR. Although conﬂicting
data on the effects of traditional HMGCR inhibitors in ApoE−/−
mice exist- (i) statins were shown to have no effect, an increasing
Fig. 4. Leoligin upregulates hepatic HMG-CoA-reductase expression after 16weeks of treatment inApoE−/−mice. (A)Hepatic HMGCR expression is given as positive area per hepatocyte
after 2 weeks of treatment with leoligin and vehicle control (n = 4 per group)§. 5 images per mouse were evaluated. (B) ApoE−/− mouse livers were stained with an anti-HMGCR
antibody and an appropriate secondary antibody (green signal). Cell nuclei were stained with PI (red signal). Representative images are shown. (C) Hepatic HMGCR expression is
given as positive area per hepatocyte after 16 weeks of treatment with leoligin and vehicle control (control: n = 9, Leoligin 1 μM: n = 9, Leoligin 10 μM: n = 8, Leoligin 50 μM: n =
7). 5 images per mouse were evaluated. (D) ApoE−/− mouse livers were stained with an anti-HMGCR antibody and an appropriate secondary antibody (green signal). Cell nuclei
were stained with PI (red signal). Representative images are shown. §The two week samples originate from a separate experiment which included a 100 μM group instead of a 50 μM
group. *Indicates p b 0.05, **p b 0.01, and ***p b 0.001.
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gested that statins decrease atherosclerotic plaque formation inde-
pendent of their impact on cholesterol levels [29–31] - we thinkFig. 5.Oil RedO staining of liver cryosections, their quantiﬁcation, relative liver weight and expr
were stained with Oil Red O to quantify intrahepatic lipids and esteriﬁed cholesterol depositio
positive area in percentage of whole liver area. 5 images per mouse/liver were evaluated (cont
additional parameter for liver fat accumulation, the relative liver weight (% liver weight of whol
10 μM: n = 9, Leoligin 50 μM: n = 7). (D) ApoE−/− mouse liver lysates were separated on
antibodies. Representative blots are shown at 254 kDa (ABCA-1), 82 kDa (SR-B1), and 160 kDathat leoligin, which is not a statin and does not have a statin-like
structure, decreases cholesterol levels through direct inhibition of
HMGCR in vivo.ession of hepatic ABCA-1, SR-B1 and LDL-receptor. (A) ApoE−/−mouse liver cryosections
ns (red). Representative images are shown. (B) Hepatic lipid content is given as Oil Red O
rol: n = 9, Leoligin 1 μM: n= 9, Leoligin 10 μM: n = 8, Leoligin 50 μM: n= 7). (C) As an
e bodyweight) wasmeasured and analysed (control: n= 8, Leoligin 1 μM: n= 9, Leoligin
an SDS-PAGE, blotted onto a nitrocellulose membrane and then stained with different
(LDL-R). *p b 0.05, **p b 0.005.
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Fig. 6. Leoligin reduces blood glucose peak levels in ApoE−/− mice. Intraperitoneal
glucose tolerance test was performed (A) after 2 weeks of treatment and (B) after
16 weeks of treatment in ApoE−/− mice treated with leoligin and vehicle control
(n = 5 per group), respectively. *p b 0.05, **p b 0.01.
44 B. Scharinger et al. / Journal of Molecular and Cellular Cardiology 99 (2016) 35–46In silico docking and modelling studies suggest that binding of
leoligin to HMGCR may be unconventional. In detail, common feature
pharmacophore model ﬁtting and the docking show that leoligin com-
petitively occupies the active site of HMGCR similar to the currently
used statins. However, although it binds at a similar location it does
not establish the same interaction pattern as statins. Typically, statins
contain an opened lactone ring and can therefore form an ionic interac-
tion with Arg590 in the binding site. Due to the lack of an acidic moiety
in leoligin, this charged interaction is replaced by hydrogen bonds be-
tween two methoxy groups of leoligin and Arg590. According to the
proposed binding mode there is still space adjacent to the leoligin mol-
ecule after locking into its binding site. Therefore, hydrophobic substitu-
tion of leoligin's ester side chain may increase its activity against
HMGCR.
In vivo the cholesterol-lowering effects of leoligin were found
after 2 and 5 weeks of treatment, but not after 16 weeks. Endo et
al. previously described a marked and compensatory hepatic
induction of HMGCR expression in mice under statin treatment
[32]. Our immunoﬂuorescent analyses of liver tissue also showed a
strong upregulation of HMGCR after 16 weeks of treatment in
the leoligin groups, resulting in a signiﬁcantly increased hepatic
lipid/cholesterol deposition in the 1 μM leoligin group. This hepatic
counterregulation could explain the lack of an enduring leoligin
effect on cholesterol levels. Moreover, we observed a constant
decrease in serum cholesterol levels in the control group over time,
which may mask the cholesterol-lowering effects of leoligin.Despite the beneﬁcial effects of leoligin described above, histological
analyses of atherosclerotic plaque area and plaque structure/composi-
tion showed no protective effect. Based on this discrepancy we hypoth-
esize that the increased hepatic HMGCR expression resulting in
unchanged cholesterol levels at the endpoint may have overruled po-
tential anti-atherogenic effects of leoligin. Importantly however, we
need to reinforce that the relationship between pharmaceutical
targeting of the HMGCR with its subsequent inﬂuence on cholesterol
levels and its effects on atherosclerotic plaque formation in ApoE−/−
mice remains controversial [29].
Our results showed that leoligin potently decreases serum glucose
peaks after intraperitoneal glucose injection in ApoE−/−micewithout
inﬂuencing fasting glucose. Elevated postprandial glucose peaks have
been identiﬁed to be a risk factor for CVDs (even in the absence of ele-
vated fasting glucose), also in non-diabetic patients. There is evidence
that aggressive treatment of postprandial hyperglycaemia may be nec-
essary to reduce this risk [33]. To elucidate the mechanisms of action
by which leoligin decreases peak glucose levels, we investigated a po-
tential interaction with PPAR-γ activity, a known target of the anti-dia-
betic glitazones as reviewed by Ahmadian et al. [34]. In a cell-based in
vitro assay, leoligin was able to increase PPAR-γ activity in control
cells and also in cells treated with the PPAR-γ antagonist GW9662. On
the contrary, leoligin decreased rosiglitazone induced PPAR-γ activity.
Based on these results, we suggest that leoligin is a weak PPAR-γ ago-
nist, which could explain its effects on blood peaks glucose levels. Fur-
ther we suggest that leoligin, when combined with the strong agonist
rosiglitazone – by competition for the PPAR-γ binding sites – reduces
rosiglitazone induced PPAR-γ activity. Further, in silico docking and
modelling and most of all biochemical assays are needed to precisely
deﬁne the observed phenomena. Interestingly, the peak glucose reduc-
ing effects of leoligin, similar to the loss of cholesterol lowering activity,
also vanished after 16 weeks. Again, a possible counterregulatory effect
as demonstrated for hepatic HMGCR might be at play. Nevertheless, a
common and central process such as drug metabolisation may lead to
the loss of activity of leoligin in both phenomena. As leoliginwas not de-
tectable by GC–MS analyses inmouse serum (LOD 0.5 μM) or liver sam-
ples (LOD 1 μM), the question whether differing enzymatic degradation
of leoligin is relevant for the ceasing activity after 16weeks has yet to be
answered. Regarding the reduction of serum cholesterol levels we pro-
vided data that concentration as low as 0.5 μM leoligin still potently in-
hibits HMGCR enzyme activity.
In our previous study using oral leoligin application and CETP ex-
pressing mice [16], leoligin could be detected in the circulation, clearly
showing the transport of leoligin from the digestive tract into the circu-
lation. Given the fact that CETP is a blood circulating protein which
binds leoligin [16], it is assumed that CETP, which is not expressed in
wild type and ApoE−/− mice, might stabilize leoligin in, or reduce
clearance from the circulation. Accordingly, it is hypothesized that
leoligin enters the circulation through the digestive tract and is present
in the serum of ApoE−/−mice, but may be - by binding to the intracel-
lular HMGCR - “cleared” from the circulation. Importantly, other mech-
anisms by which leoligin interferes with serum lipid levels may be at
play. The assessment of in vivo cholesterol metabolism (by radioactive
labelling of cholesterol) combined with the study of a potential inhibi-
tion of cholesterol uptake in the gut may shed light on these potentially
additional mechanisms.
Another effect of leoligin that could be observed – but not explained
– in the course of the present project was that in the 50 μM leoligin
group treatment resulted in reduced weight gain of animals. In order
to exclude reduced food consumption by the 50 μM leoligin group ani-
mals, food consumption per animalwas analysed and found to not differ
compared to the other groups. Further we analysed a signiﬁcant num-
ber of parameters (i.e. BUN, AST, ALT, LDH, CK), which indicate organ
toxicity. None of these parameters was increased in leoligin treated an-
imals, suggesting that leoligin is not toxic to Apo E−/−mice when ap-
plied orally over 16 weeks and up to 50 μM.
Fig. 7. Leoligin is a weak PPAR-γ agonist in vitro and molecular modelling and docking of leoligin to PPAR-γ suggests a similar binding mode as described for pioglitazone. Leoligin (A)
slightly increases PPAR-γ activity when applied alone, (B) signiﬁcantly decreases PPAR-γ activity when combined with a PPAR-γ agonist (rosiglitazone) and (C) reverses PPAR-γ
antagonism (antagonist used: GW9662). *p b 0.05. (D) The three most similar predicted binding poses of leoligin (cyan) superimposed on the X-ray structure of pioglitazone (grey)
bound to the PPAR-γ ligand binding domain (pocket). (E) and (F) 2D and 3D predicted protein-ligand interactions between leoligin and the PPAR-γ ligand binding domain. The ligand
forms two hydrogen bond acceptors with Cys285 and Ser342, respectively (red arrows). Additionally, extensive hydrophobic contacts are established (yellow spheres).
45B. Scharinger et al. / Journal of Molecular and Cellular Cardiology 99 (2016) 35–46With the positive effects of leoligin on serum cholesterol, peak glu-
cose levels, andweight gain reported in this study, aswell aswith its in-
timal hyperplasia inhibiting properties and its CETP-modulating
activity, we think that leoligin possesses anti-atherogenic characteris-
tics which are of high interest. Since dyslipidaemia, hyperglycaemia,
and obesity are major risk factors in the pathogenesis of atherosclerosis
and CVD, leoliginmay be a novel and potential therapeutic agent for pri-
mary and secondary prevention. Without doubt, many more studies
and analyses are needed prior to the ﬁrst study in human.
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